Financial statement January 1 to December 31 2020
Faron Pharmaceuticals Oy (“Faron” or the “Company”) Financial statement release January 1 to December 31, 2020 ·Clevegen[®] (bexmarilimab) Phase I/II MATINS study has shown early clinical benefits in six hard-to-treat solid cancers with further combination studies planned · Intravenous interferon beta-1a Traumakine[®], for organ damage protection, now also investigated as potential COVID-19 treatment · Company’s balance sheet strengthened by successful share placings of €14 million and €15 million (post period) · Additional grants of €3.3 million and €4.6 million